Prof . Sihe Zhang | drug delivery | Best Scholar Award 

Director , Nankai University , China

Si-he Zhang is a tenured full professor at Nankai University’s School of Medicine, Department of Cell Biology. With extensive experience in cell biology, genetics, and oncology, his research focuses on cancer biology, antibody and vaccine research, and targeted cancer therapies. He has made significant contributions to the field through numerous publications, patents, and major research grants.

Profile

Scopus

Strengths for the Award

1. Extensive Research Experience: Si-he Zhang has over two decades of research experience in cell biology, genetics, and cancer research. This depth of experience is evident in the numerous high-impact publications, many of which focus on cutting-edge therapeutic strategies for cancer.
2. Notable Awards and Recognitions: Zhang has been recognized with prestigious awards, including the National Prize for Progress in Science & Technology in China and the Gold Award for Chinese Outstanding Patented Invention, which underscore his contributions to scientific advancement.
3. Leadership and Influence: Zhang has held significant academic positions, such as a tenured full professorship at Nankai University, and has been involved in important scholarship committees. His role as a consultant to industry leaders further highlights his influence in both academic and industrial biotechnology sectors.
4. Impressive Grant Record: Zhang has secured numerous major grants from national and regional funding bodies in China, which is a testament to his ability to lead and sustain high-impact research projects.
5. Innovative Research Contributions: Zhang’s research has led to the development of novel therapeutic strategies and technologies, including hypoxia-activated antibodies for cancer treatment and suicide gene delivery methods for ovarian cancer therapy. These contributions are of significant value to the medical and scientific community.

Areas for Improvement

1. Global Collaboration: While Zhang has extensive experience within China and some international experience (e.g., postdoctoral work in Sweden), expanding collaborations with a broader range of international research institutions could enhance the global impact of his work.
2. Diversity of Research Topics: Zhang’s research is highly focused on cancer biology and cell biology. Expanding into related fields or interdisciplinary areas could further broaden the scope and application of his research, increasing its relevance to other fields of biomedical science.
3. Teaching and Mentorship: Although Zhang has a strong teaching portfolio, highlighting specific outcomes or successes of his students and mentees could strengthen his case for an award focused on scholarly excellence, particularly if they have gone on to significant achievements under his guidance.
   

   Education

   • PhD in Cell Biology (2001-2004) from the Fourth Military Medical University, China.
   • M.A. in Genetics (1996-1998) from Jilin University, China.
   • B.S. in Genetics (1991-1995) from Northwest A&F University, China.

   Experience

   • Tenured Full Professor at Nankai University (2020-present).
   • Tenured Associate Professor at Nankai University (2012-2019).
   • Postdoctoral Scientist at Lund University Hospital, Sweden (2006-2009).
   • Associate Professor and Lecturer at Fourth Military Medical University (2000-2011).
   • Teaching Assistant at Fourth Military Medical University (1998-2000).

   Research Interests

   Si-he Zhang’s research encompasses cancer biology, cell engineering, and transgenic biology. He focuses on the development of novel therapeutic strategies for cancer treatment, including antibody-based therapies and targeted drug delivery systems.

   Awards

   • Gold Award for Chinese Outstanding Patented Invention (2010), WIPO-SIPO.
   • National Prize for Progress in Science & Technology (2005), China.

   Publications

   1. Hypoxia-activated ADCC-enhanced humanized anti-CD147 antibody for liver cancer imaging and targeted therapy (2024), MedComm, Cited by 5 articles.
   2. Hypoxia-activated selectivity-improved anti-PKM2 antibody for hepatocellular carcinoma (2024), International Journal of Biological Sciences, Cited by 3 articles.
   3. Suicide Gene Delivery by Morphology-Adaptable Enantiomeric Peptide Assemblies (2024), Acta Biomaterialia, Cited by 7 articles.
   4. Novel GIRlncRNA Signature for Predicting Clinical Outcome in NSCLC (2022), Frontiers in Pharmacology, Cited by 15 articles.
   5. GRP75-driven macropinocytosis of Tat/pDNA-Ca2+ nanoparticles in ovarian cancer (2022), Journal of Nanobiotechnology, Cited by 8 articles.
      

      Conclusion

      Si-he Zhang is a highly qualified candidate for the Best Scholar Award, with a robust record of research, significant contributions to cancer therapy, and notable academic leadership. His extensive publication history, major awards, and successful acquisition of research funding demonstrate his impact in the field of cell biology and cancer research. However, to further strengthen his candidacy, he could consider increasing his global collaborations and diversifying his research interests. Overall, Zhang’s accomplishments make him a strong contender for the award, reflecting his dedication to advancing scientific knowledge and medical innovation.